VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
PHG
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
PHGKoninklijke Philips N.V.
$28.23$26.9B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksPHGPrice Target
PHG logo

Koninklijke Philips N.V. (PHG) Price Target Analysis

Analyst Rating: Hold
Based on 22 analysts

No Target Data

PHG trades at Wall Street's consensus target of —.

Current Price$28.23
Average Target—
Low—
Median—
High—

Analyst Target Range

Forward P/E18.2x
(Fair)
PEG Ratio—
Implied Growth+54.6%
(High Growth)
Analyst Spread—

Price Forecast (1 Year)

Last 12 months price action with 12-month analyst target path

Current$28.23
Consensus—
High—
Low—

Consensus Scenario Assumptions

The base valuation assumes PHG achieves its forward estimates and maintains a stable P/E multiple of 18.2x. This scenario reflects the blended consensus of 22 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.

Analyst Ratings Distribution

Breakdown of 22 published analyst recommendations for PHG

59% hold / mixed conviction
+20
BearishBullish
Weighted analyst sentiment score based on 22 ratings
ConsensusHold
Coverage22 Analysts
Net Score+20
Bull / Bear41% / 0%
Strong Buy00%
Buy941%
Hold1359%
Sell00%
Strong Sell00%
Strong Buy
00%
Buy
941%
Hold
1359%
Sell
00%
Strong Sell
00%
Recommendation Mix41% Buy · 59% Hold · 0% Sell
Buy (9)Hold (13)Sell (0)

PHG Price Target Analysis

Updated July 8, 2026

As of July 8, 2026, Koninklijke Philips N.V. (PHG) has a Wall Street consensus price target of N/A, based on estimates from 22 covering analysts. The company has a market capitalization of $26.88B.

Analyst price targets range from a low of N/A to a high of N/A.

The current analyst consensus rating is Hold, with 9 analysts rating the stock as a Buy or Strong Buy,13 rating it Hold, and 0 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.

From a valuation perspective, PHG trades at a trailing P/E of 26.6x and forward P/E of 18.2x. Analysts expect EPS to grow +54.6% over the next year.

Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $8.86, with bear and bull scenarios of $5.58 and $11.68 respectively. Model confidence stands at 45/100, suggesting limited visibility into future performance.

Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.

Analyst Sentiment Comparison

Industry Peer Analysis
Avg Peer Upside
+20.0%
Industry Consensus
Avg Forward P/E
22.0x
(Fair)
Peers with Coverage
10 / 10
Active Analyst Tracking
CompanyMarket CapPriceTargetUpside PotentialRatingFwd P/EAnalysts
SYK logo
SYKStryker Corporation
$120.1B$313.38$387.46
+23.6%
Buy20.9x51
BSX logo
BSXBoston Scientific Corporation
$67.3B$45.30$82.40
+81.9%
Buy13.5x44
EW logo
EWEdwards Lifesciences Corporation
$54.6B$94.82$97.45
+2.8%
Buy31.5x48
BAX logo
BAXBaxter International Inc.
$11.8B$22.86$20.71
-9.4%
Hold11.9x36
ZBH logo
ZBHZimmer Biomet Holdings, Inc.
$17.5B$89.41$96.33
+7.7%
Hold10.5x42
MDT logo
MDTMedtronic plc
$107.6B$83.83$95.80
+14.3%
Buy14.1x51
GE logo
GEGE Aerospace
$383.4B$366.98$393.00
+7.1%
Buy48.6x34
GEHC logo
GEHCGE HealthCare Technologies Inc.
$29.5B$64.89$81.00
+24.8%
Buy13.3x18
HAE logo
HAEHaemonetics Corporation
$3.5B$74.88$80.33
+7.3%
Buy15.1x21
ISRG logo
ISRGIntuitive Surgical, Inc.
$151.3B$427.30$597.78
+39.9%
Buy40.9x55

PHG — Frequently Asked Questions

Quick answers to the most common questions about buying PHG stock.

What is the PHG stock price target for 2026?

The consensus price target for PHG is $N/A, close to the current price of $28.23 (N/A% implied move). Based on 22 analyst estimates, the stock appears fairly valued near current levels.

Is PHG a buy, sell, or hold?

PHG has a consensus rating of "Hold" based on 22 Wall Street analysts. The rating breakdown is mixed, with 13 Hold ratings making up the largest segment. The consensus 12-month price target of $N/A implies N/A% upside from current levels.

Is PHG stock overvalued or undervalued?

With a forward P/E of 18.1883x, PHG trades at a relatively low valuation. The consensus target of $N/A implies N/A% appreciation, suggesting the market may be pricing in risks.

How high can PHG stock go?

The most bullish Wall Street analyst has a price target of $N/A for PHG, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. Our quantitative valuation model projects a bull case target of $12 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

How many analysts cover PHG stock?

PHG is well covered by analysts, with 22 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 9 have Buy ratings, 13 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

What is the PHG stock forecast?

The 12-month PHG stock forecast based on 22 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $9, with bear/bull scenarios of $6/$12.

What is PHG's fair value based on fundamentals?

Our quantitative valuation model calculates PHG's fair value at $9 (base case), with a bear case of $6 and bull case of $12. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 45/100.

What is PHG's forward P/E ratio?

PHG trades at a forward P/E ratio of 18.2x based on next-twelve-months earnings estimates compared to a trailing P/E of 26.6x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

Should I buy PHG stock?

PHG appears fairly valued according to analysts, with a "Hold" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

Why do PHG price targets vary so much?

PHG analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground. Our model's $6-$12 range provides an independent fundamental perspective.

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare